Abstract: The present invention relates to a method for prediction of response to cardiovascular regeneration comprising the use of biomarkers. Further, the present invention relates to a combination of the biomarkers for use in a method for prediction of response to cardiovascular regeneration, a computer device to perform a method according to the present invention and a device adapted for carrying out the inventive method.

Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Abstract: A method includes: receiving a mathematical model of a control system, with state variables and control parameters; discretizing at least a part of a space to obtain a set of tuples; determining for each tuple at least one successor state; obtaining an initial winning set of tuples; determining an updated winning set of tuples, including comparing the at least one successor state with the initial winning set of tuples, where the comparison is distributed over available processing elements by choosing one processing element from the available processing elements for each tuple to perform the comparison and where the available processing elements are used simultaneously at least in part; repeating the determination of the updated winning set of tuples to obtain a new updated winning set of tuples if a convergence measure does not meet a criterion, and constructing a controller for the control system from the new updated winning set.

Abstract: The present invention relates to the novel use of saponins having acetyl residues on one of their sugar residues. These saponins are able to enhance the transfection efficiency to a surprisingly much higher extent than already known saponins and even than Lipofectamin.

Abstract: The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: Systems and methods for transmitting data using various Modulation on Zeros schemes are described. In many embodiments, a communication system is utilized that includes a transmitter having a modulator that modulates a plurality of information bits to encode the bits in the zeros of the z-transform of a discrete-time baseband signal. In addition, the communication system includes a receiver having a decoder configured to decode a plurality of bits of information from the samples of a received signal by: determining a plurality of zeros of a z-transform of a received discrete-time baseband signal based upon samples from a received continuous-time signal, identifying zeros that encode the plurality of information bits, and outputting a plurality of decoded information bits based upon the identified zeros.

Abstract: The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four ?-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming ?-helices that are located on the same polypeptide chain, wherein each amino acid linker has a length between 2 and 20 amino acids. The invention also provides for a polynucleotide and a vector encoding the protein of the invention, host cells comprising said polynucleotide, a method for producing the protein of the invention and a pharmaceutical composition comprising the protein of the invention. The invention further relates to uses of the proteins of the invention as a research reagent and the use of the protein and/or pharmaceutical composition comprising the same as a medicament, e.g., for use in increasing stem cell production, for use in inducing hematopoiesis and/or for use in mobilizing hematopoietic stem cells.

Abstract: The invention relates to a liquid metal-ion beam system (1) or liquid metal electron beam system, including: a conductive emitter electrode (2), a conductive extractor electrode (3) opposite to the emitter electrode (2), a liquid metal reservoir (4) which is fluidically connected to the emitter electrode (2) for transporting liquid metal to the emitter electrode (2), a control unit (5) which is configured to apply a periodically varying operating voltage between emitter electrode (2) and extractor electrode (3).

Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

Abstract: The present invention relates to methods for diagnosing, staging and treating cancer, in particular melanoma. In particular, the present invention provides methods for determining the stage/type of a cancerous disease, comprising detecting somatic alterations of the DNA of one or more disseminated cancer cells (DCCs), obtained after homing to a distant organ, such as lymph node; and determining the somatic evolution of the DCC(s) based on the detected somatic alterations, wherein the somatic evolution is indicative of the stage/type of the cancerous disease.

Abstract: The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of repeated domains of a heterologous protein or two or more domains of different heterologous proteins into eukaryotic cells.

Abstract: The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a compound capable of enhancing transduction efficiency or a combination of such compounds, wherein the target cell is pre- and/or co-stimulated by pre- and/or co-incubation with said transduction enhancing compound or a combination of transduction enhancing compounds prior to and/or during contacting the target cell with the retroviral vector.

Abstract: A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user’s behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user’s behavioral model using the first algorithm, providing a customized user’s behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user’s behavioral model.

Abstract: An electronic circuit having a semiconductor device is provided that includes a heterostructure, the heterostructure including a first layer of a compound semiconductor to which a second layer of a compound semiconductor adjoins in order to form a channel for a 2-dimensional electron gas (2DEG), wherein the 2-dimensional electron gas is not present. In aspects, an electronic circuit having a semiconductor device is provided that includes a III-V heterostructure, the III-V heterostructure including a first layer including GaN to which a second layer adjoins in order to form a channel for a 2-dimensional electron gas (2DEG), and having a purity such that the 2-dimensional electron gas is not present. It is therefore advantageous for the present electronic circuit to be enclosed such that, in operation, no light of wavelengths of less than 400 nm may reach the III-V heterostructure and free charge carriers may be generated by these wavelengths.

Abstract: A method for a treatment of individuals suffering from diseases associated with sulfatase deficiencies including lysosomal storage disease includes administering at least once a therapeutically effective amount of at least one retinoid. In particular, the compounds tazaroten and bexaroten have beneficial effects on these individuals. Pharmaceutical compositions comprising both active agents namely, tazaroten and bexaroten compounds, or similar compounds, provides for ready treatment of such individuals, and enhanced treatment is achieved with at least two active agents.

Abstract: The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer treatment or prevention.

Abstract: The invention relates to a method for providing a medication combination, wherein at least one medication of the medication combination to be provided is selected on the basis of the result of a molecular in vitro characterization of tumor tissue of a glioblastoma of a patient. The selection is made on the basis of eliminating and not selecting medications from a list of non-oncological medications for which no benefit has been acknowledged for treating the patient on the basis of the result of the molecular in vitro characterization. The medication combination which can be provided using the method is inexpensive, exhibits a low degree of toxicity, and is characterized by an improved efficacy in comparison to known medication combinations. The invention additionally relates to a data carrier with software which can support or simplify the process of carrying out the method according to the invention.

Abstract: The present invention relates to a contrast agent suitable for ex vivo imaging, particularly of vascular structures and renal tubular structures, and a method for ex vivo imaging. The contrast agent is a polymer comprising monomers M. The monomer comprises a backbone having 2 to 6 elements, wherein at least one element is —CH(R)— or —N(R)—. R is a moiety -E-H, -L-(NH2)m or a moiety of formula 1, with E, L, R1 and R2 being defined as described in the present specification. The monomer comprises at least one —I to allow detection via X-ray and at least one —NH2 to allow crosslinking. Furthermore, the monomer comprises polar functional groups that contribute to water solubility. To avoid extravasation and glomerular filtration, the polymers are pre-crosslinked before the vasculature of a tissue, an organ or whole animal is perfused. After perfusion, the pre-crosslinked contrast agent is further crosslinked to be retained within the tissue, organ or animal permanently.

Abstract: Disclosed herein are embodiments of a compound useful for treating or preventing SARS-Cov-2 infections. Also disclosed is a method for administering the compound to a subject, particularly a human subject, to treat or prevent a SARS-CoV-2 infection in the subject. The compound may comprise an oligomer comprising a nucleic acid base sequence that is antisense to a gene, pre-mRNA or mRNA in the subject, such as a gene, pre-mRNA or mRNA of transmembrane serine protease 2 (TMPRSS2). The compound also may comprise a peptide sequence. In some embodiments, the compound is a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).